Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed Inc. is demonstrating strong financial growth, with a notable 98% increase in third-quarter revenue, reaching $13.1 million, propelled by a significant rise in its surgeon user base, which grew by over 70% year-over-year. The company's gross margin of 75.9% outperformed forecasts, benefiting from reductions in contract manufacturing costs and inventory reserve expenses, indicating operational efficiency. Furthermore, a sustained compound annual growth rate (CAGR) of over 50% in revenue is projected from 2024 to 2028, supported by the expansion into a $13.4 billion U.S. lumbar fusion market and planned advancements into the cervical market.

Bears say

The financial outlook for Carlsmed Inc. is negatively impacted by anticipated revenue challenges, with FY26 estimates for cervical revenue projected at $2.9 million, falling short of the original estimate of $3.4 million due to potential slower adoption of the aprevo platform by new surgeons. Contributing to this unfavorable forecast are several risks, including a lower growth rate within the overall spine market, accelerated degradation of average selling prices, delayed entry into the cervical spine market, and higher-than-expected operating expenses. Additionally, competitive pressures from larger companies and changes in reimbursement policies could further jeopardize Carlsmed's market share and pricing power, with the company experiencing a significant EBITDA loss of $30.7 million.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Jan 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.